- Home
- App-Analyse
- Obvio Hub
- Obvio Hub Vs. PatienTrials
Obvio Hub im Vergleich zu PatienTrials Nutzung und Statistiken
Obvio Hub is a proprietary platform of ObvioHealth used to manage decentralized and hybrid clinical trials. The result? Robust data collection, increased compliance, faster time to completion, and average cost savings of ~50% vs. traditional on-site trials
The Obvio Hub app facilitates the successful and secure operation of virtual clinical trials by allowing the study team to monitor the trial's progress, view data insights, and complete trial tasks. The app provides the full range of functionality offered in the web interface.
- Apple App Store
- Kostenlos
- Gesundheit und Fitness
Rang speichern
- -
PatienTrials helps pharma companies and clinicians run global clinical trials virtually, more efficiently in a closed community setting over HIPAA & GDPR compliant collaboration platform. PatienTrials aims to improve patient adherence by empowering participants with information on the progress of treatment at their fingertips in a community setting, that promotes self-care. PatienTrials captures high-quality patient generated data through solutions based on instant messaging, HealthKit, AI and bots, is poised to make a positive impact on drug development. Monitored by proprietary AI agent for adverse events, PatienTrials reduces study risk and lowers development costs. Founded in 2016, PatienTrials is the first company to bring clinical trials on to a HIPAA & GDPR compliant instant messaging platform.
- Apple App Store
- Kostenlos
- Medizin
Rang speichern
- -
Obvio Hubvs. PatienTrials Ranking-Vergleich
Vergleichen Sie Obvio Hub den Ranking-Trend der letzten 28 Tage mit PatienTrials
Rang
Keine Daten verfügbar
Obvio Hub im Vergleich zu PatienTrials Ranking im Ländervergleich
Vergleichen Sie Obvio Hub den Ranking-Trend der letzten 28 Tage mit PatienTrials
Keine Daten zum Anzeigen
Stellen Sie mit unserer kostenlosen Testversion Vergleiche mit jeder Website an
Obvio Hub VS.
PatienTrials
Dezember 18, 2024